Brief: Maat Pharma: 1st Patient Dosed In Phase 2B Randomized Clinical Trial Evaluating MaaT033

Maat Pharma SA

06/11/2023 06:34

Nov 6 (Reuters) - Maat Pharma SA  MAAT.PA :
    * MAAT PHARMA ANNOUNCES FIRST PATIENT DOSED IN PHASE 2B
RANDOMIZED
CLINICAL TRIAL EVALUATING MAAT033 IN PATIENTS RECEIVING
ALLO-HSCT
    * ANNOUNCED TODAY THAT FIRST PATIENT HAS BEEN TREATED AS
PART OF
ITS PHASE 2B TRIAL
    * TO DATE, COMPANY HAS RECEIVED REGULATORY APPROVALS FROM
FRANCE
AND GERMANY, AND CLINICAL TRIAL WILL BE EXPANDED TO SITES IN
ADDITIONAL COUNTRIES SUBJECT TO REGULATORY APPROVAL

Source text for Eikon:  ID:nBw6lgq90a 
Further company coverage:  MAAT.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))